胆固醇通过减弱孕激素信号传导使子宫内膜癌对孕激素治疗脱敏
该研究分析血清脂质差异发现,孕激素抵抗的子宫内膜癌(EC)/子宫内膜不典型增生(EAH)患者血清载脂蛋白A-I降低且内膜组织胆固醇蓄积增加。机制上细胞胆固醇与孕激素竞争结合孕激素受体B(PRB),损害其磷酸化、核转位及下游基因激活。瑞舒伐他汀钙降脂治疗在动物模型及单臂开放标签2期临床试验中恢复孕激素敏感性,提示胆固醇蓄积参与孕激素抵抗,孕激素联合他汀可能增强EC疗效。
要点
- 孕激素抵抗的EC/EAH患者血清载脂蛋白A-I降低、内膜组织胆固醇蓄积增加
- 细胞胆固醇竞争性结合PRB,干扰孕激素信号传导
- 瑞舒伐他汀钙在动物模型及单臂开放标签2期试验中恢复孕激素敏感性
核心结论
- 胆固醇蓄积参与孕激素抵抗,孕激素联合他汀可能增强EC治疗疗效。
研究设计与样本
- 研究包括血清脂质差异分析、分子对接模拟、细胞模型、动物模型及单臂开放标签2期临床试验。
主要发现
- 孕激素抵抗的EC/EAH患者血清载脂蛋白A-I浓度降低且子宫内膜组织胆固醇蓄积增加。
- 细胞胆固醇与孕激素竞争结合PRB,损害PRB磷酸化、核转位及下游基因激活。
- PRB中亮氨酸887被丙氨酸887替换可破坏胆固醇结合但保留孕激素反应性。
- 瑞舒伐他汀钙降脂治疗在动物模型和单臂开放标签2期临床试验中恢复孕激素敏感性。
关键数值与推荐
- 孕激素抵抗的EC/EAH患者血清载脂蛋白A-I浓度降低且内膜组织胆固醇蓄积增加。
- PRB亮氨酸887替换为丙氨酸887破坏胆固醇结合并保留孕激素反应性。
临床怎么用
- 作者认为孕激素联合他汀可能增强EC治疗疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Progestin is the primary fertility-preserving treatment for patients with endometrial cancer (EC) and its precursor lesions, endometrial atypical hyperplasia (EAH); however, a subset of patients exhibits a poor response. In this study, through the analysis of serum lipid differences, we found that progestin-resistant patients with EC/EAH exhibited reduced serum apolipoprotein A-I concentrations and increased cholesterol accumulation in endometrial tissue. Mechanistically, molecular docking simulations and cellular models confirmed that cellular cholesterol interfered with progestin-driven signaling by competing with progestin for binding to progesterone receptor B (PRB), thereby impairing its phosphorylation, nuclear translocation, and downstream gene activation. Substitution of leucine887 with alanine887 in PRB disrupted cholesterol binding but preserved progestin responsiveness. Furthermore, cholesterol-lowering therapy with rosuvastatin calcium restored progestin sensitivity in animal models and in a single-arm, open-label phase 2 clinical trial. Our work shows that cholesterol accumulation contributes to progestin resistance and that combining progestin with statins may enhance therapeutic efficacy in EC.
引用
- Hu J, Wang L, Yang B, et al. Cholesterol desensitizes the response of endometrial cancer to progestin by attenuating progestin signaling. Sci Transl Med. 2025. PMID: 41032624. doi:10.1126/scitranslmed.adp0064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。